Literature DB >> 21698392

Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.

Lars Egevad1, Ferran Algaba, Daniel M Berney, Liliane Boccon-Gibod, Eva Compérat, Andrew J Evans, Rainer Grobholz, Glen Kristiansen, Cord Langner, Gina Lockwood, Antonio Lopez-Beltran, Rodolfo Montironi, Pedro Oliveira, Matthias Schwenkglenks, Ben Vainer, Murali Varma, Vincent Verger, Philippe Camparo.   

Abstract

Our aims were to analyze reporting of Gleason pattern (GP) 3 and 4 prostate cancer with the ISUP 2005 Gleason grading and to collect consensus cases for standardization. We scanned 25 prostate biopsy cores diagnosed as Gleason score (GS) 6-7. Fifteen genitourinary pathologists graded the digital slides and circled GP 4 and 5 in a slide viewer. Grading difficulty was scored as 1-3. GP 4 components were classified as type 1 (cribriform), 2 (fused), or 3 (poorly formed glands). A GS of 5-6, 7 (3 + 4), 7 (4 + 3), and 8-9 was given in 29%, 41%, 19%, and 10% (mean GS 6.84, range 6.44-7.36). In 15 cases, at least 67% of observers agreed on GS groups (consensus cases). Mean interobserver weighted kappa for GS groups was 0.43. Mean difficulty scores in consensus and non-consensus cases were 1.44 and 1.66 (p = 0.003). Pattern 4 types 1, 2, and 3 were seen in 28%, 86%, and 67% of GP 4. All three coexisted in 16% (11% and 23% in consensus and non-consensus cases, p = 0.03). Average estimated and calculated %GP 4/5 were 29% and 16%. After individual review, the experts met to analyze diagnostic difficulties. Areas of GP 4 and 5 were displayed as heat maps, which were helpful for identifying contentious areas. A key problem was to agree on minimal criteria for small foci of GP 4. In summary, the detection threshold for GP 4 in NBX needs to be better defined. This set of consensus cases may be useful for standardization.

Entities:  

Mesh:

Year:  2011        PMID: 21698392     DOI: 10.1007/s00428-011-1106-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  18 in total

1.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

Authors:  W C Allsbrook; K A Mangold; M H Johnson; R B Lane; C G Lane; J I Epstein
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

2.  Current practice of Gleason grading among genitourinary pathologists.

Authors:  Lars Egevad; William C Allsbrook; Jonathan I Epstein
Journal:  Hum Pathol       Date:  2005-01       Impact factor: 3.466

Review 3.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

4.  The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

5.  Randomized comparison of virtual microscopy and traditional glass microscopy in diagnostic accuracy among dermatology and pathology residents.

Authors:  Laine H Koch; James N Lampros; Laura K Delong; Suephy C Chen; John T Woosley; Antoinette F Hood
Journal:  Hum Pathol       Date:  2009-01-14       Impact factor: 3.466

6.  The impact of the 2005 international society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies.

Authors:  Athanase Billis; Marbele S Guimaraes; Leandro L L Freitas; Luciana Meirelles; Luis A Magna; Ubirajara Ferreira
Journal:  J Urol       Date:  2008-06-11       Impact factor: 7.450

7.  Observer variability in the histopathological reporting of needle biopsy specimens of the prostate.

Authors:  A M Lessells; R A Burnett; S R Howatson; S Lang; F D Lee; K M McLaren; E R Nairn; S A Ogston; A J Robertson; J G Simpson; G D Smith; H B Tavadia; F Walker
Journal:  Hum Pathol       Date:  1997-06       Impact factor: 3.466

8.  Should we replace the Gleason score with the amount of high-grade prostate cancer?

Authors:  André N Vis; Stijn Roemeling; Ries Kranse; Fritz H Schröder; Theo H van der Kwast
Journal:  Eur Urol       Date:  2006-08-15       Impact factor: 20.096

9.  Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

Authors:  T A Stamey; C M Yemoto; J E McNeal; B M Sigal; I M Johnstone
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

10.  Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.

Authors:  Daniel M Berney; Gabrielle Fisher; Michael W Kattan; R Timothy D Oliver; Henrik Møller; Paul Fearn; James Eastham; Peter Scardino; Jack Cuzick; Victor E Reuter; Christopher S Foster
Journal:  BJU Int       Date:  2007-12       Impact factor: 5.588

View more
  14 in total

1.  Improving the reproducibility of the Gleason scores in small foci of prostate cancer--suggestion of diagnostic criteria for glandular fusion.

Authors:  B Helpap; G Kristiansen; M Beer; J Köllermann; U Oehler; A Pogrebniak; Ch Fellbaum
Journal:  Pathol Oncol Res       Date:  2011-12-17       Impact factor: 3.201

2.  Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.

Authors:  Trevor A Flood; Nicola Schieda; Daniel T Keefe; Rodney H Breau; Chris Morash; Kevin Hogan; Eric C Belanger; Kien T Mai; Susan J Robertson
Journal:  Virchows Arch       Date:  2016-07-10       Impact factor: 4.064

3.  Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.

Authors:  L M Wong; S Ferrara; S M H Alibhai; A Evans; T Van der Kwast; G Trottier; N Timilshina; A Toi; G Kulkarni; R Hamilton; A Zlotta; N Fleshner; A Finelli
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-12-09       Impact factor: 5.554

Review 4.  [The importance of pathology in the German prostate cancer study PREFERE].

Authors:  G Kristiansen; M Stöckle; P Albers; H Schmidberger; P Martus; S Wellek; M Härter; R Bussar-Maatz; T Wiegel
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

5.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Esther I Verhoef; Ewout W Steyerberg; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2016-03-04       Impact factor: 7.842

Review 6.  The evolving Gleason grading system.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

7.  [Diagnostic histopathology of prostate cancer].

Authors:  G Kristiansen
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

8.  Gleason score and tumor laterality in radical prostatectomy and transrectal ultrasound-guided biopsy of the prostate: a comparative study.

Authors:  Renan A Pereira; Roberto S Costa; Valdair F Muglia; Fábio Franca Silva; Joyce S Lajes; Rodolfo B Dos Reis; Gyl Eb Silva
Journal:  Asian J Androl       Date:  2015 Sep-Oct       Impact factor: 3.285

Review 9.  On cribriform prostate cancer.

Authors:  Charlotte F Kweldam; Theodorus van der Kwast; Geert J van Leenders
Journal:  Transl Androl Urol       Date:  2018-02

10.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.